Using a finely tuned cocktail of small molecules, researchers from Washington University in St. Louishave successfully converted adult skin cells into the major type of brain cell affected in the fatal neurodegenerative disorder Huntington’s disease. For the first time, this was achieved without the need to go through a stem cell intermediate, avoiding the production of other types of cell. Importantly, when the researchers transplanted these cells into the brains of mice, they survived and showed similar properties to native cells. While it is still in the early days, these preliminary results could suggest that in the future, this technique may be developed further to help patients with Huntington’s. The work has been published in Neuron.
Huntington’s disease is an inherited brain disorder that causes the progressive degeneration of nerve cells, or neurons. This disease predominantly affects a type of cell called medium spiny neurons (MSNs), which are crucial for movement control. As they are gradually lost in the brain, the patient experiences involuntary muscle movements and cognitive decline. While there is currently no cure, a future possible treatment avenue could involve replacing the lost cells in the brain. But first, researchers need to work out a way to not only produce these cells, but also to ensure they are not rejected by the patient, which is what the Washington University scientists are working towards.
Previous work by this team found that it is possible to turn skin cells into different types of brain cell by exposing them to two small molecules of RNA, a similar molecule to DNA. These specific "microRNAs” unravel target stretches of DNA, or genes, which are responsible for the identity of the cell. In doing so, proteins called transcription factors can access the DNA sequences, which result in the expression of genes which govern the development of neurons. Armed with this knowledge, the researchers added to these cells the same transcription factors present in brain regions containing MSNs. This combination of ingredients was found to result in the direct conversion of skin cells into this specific type of neuron.
“We think that the microRNAs are really doing the heavy lifting,” co-first author Matheus Victor said in a news-release. “They are priming the skin cells to become neurons. The transcription factors we add then guide the skin cells to become a specific subtype, in this case medium spiny neurons. We think we could produce different types of neurons by switching out different transcription factors.”
When the researchers analyzed these reprogrammed cells, they were found to show similar gene expression profiles to human MSNs. Furthermore, after they were transplanted into the brains of mice, they survived for over 6 months, exhibited similar properties to the native MSNs and even connected to distant neuronal targets in the brain.
The researchers are now taking this work one step further by using the same technique on skin cells taken from Huntington’s patients. To investigate whether these cells can alleviate some of the symptoms associated with the disease in animals, the researchers plan to transplant these cells into mouse models of Huntington’s.
List of all the posts
- a common misdiagnosis. (2)
- ASAP in prostate needle biopsy. (1)
- breast (2)
- Breast Biopsy Procedure (2)
- breast cancer (1)
- Breast Carcinoma vs. Pulmonary Adenocarcinoma (2)
- carcinoma (2)
- core boiopsy. (1)
- Desmoplastic melanoma (1)
- Dysplasia in Inflammatory Bowel Disease (1)
- Errors in Surgical Pathology (1)
- False positive diagnosis in breast FNAC. (1)
- FNAC (1)
- Guidelines for Radical Prostatectomy Surgical Specimen Handling (1)
- High Grade Prostatic Intraepithelial Neoplasia (HGPIN) (1)
- Immunohistochemistry in Follicular lymphoid lesions. (1)
- Immunopheotype of Gastrointestinal stromal tumours (GIST) (1)
- Importance of Tissue fixation in Cancer management (1)
- Introduction (1)
- lymph node biopsy (1)
- lymphoma (1)
- Making Sure Your Lab Reports Are Easy to Understand (1)
- Measuring size of DCIS (1)
- Microcystic adenocarcinoma of the prostate-pseudobenign carcinoma (1)
- micropapillary (1)
- Mimics of Prostate cancer (1)
- Molecular Cancer Pathology Update (1)
- Papillary Thyroid Ca Criteria (1)
- poor prognosis (1)
- Protocol for Synpotic reporting of Breast excision specimen with diagnosis of Ductal Carcinoma In Situ (DCIS) of the Breast (1)
- Quality Management Requirements for HER2/neu Marker in Breast Cancer (1)
- Quirke's Method For Dissecting Colorectal Adenocarcinoma (1)
- Reporting parameters for positive prostate needle biopsy (1)
- Research (1)
- Sentinel Lymph Node Biopsy -Malignant Melanoma (1)
- Sentinel Lymph Node Mapping-Pathology Protocol in Breast Cancer (1)
- Synoptic reporting of cancer (1)
- Updates on Molecular Cancer pathology (1)
- Work up of Carcinoma of Unknown Primary (CUP) (1)
53 years male,History of hypertension and tachycardia,MRI abdomen:-Left adrenal mass:- size 5.8 cm Right renal mass:- size-3.0cm Microscopic examination of the renal mass showed vascular tumor with diffuse sheets of clear cells having Fuhrman grade III nuclei. There was no evidence of necrosis within the tumor. There was no evidence of extraparenchymal invasion.
Gross examination of the left adrenal gland revealed cortically centered, solid and multinodular mass measuring 6.5 x 6.0 x 5.0 cm and weighing 122 grams. The tumor was encapsulated but showed evidence of extraparenchymal penetration. The tumor had golden brown cut surface with areas of hemorrhage and necrosis. The partial nephrectomy showed 3.0cm x 3.0cm x 3.0 cm yellow solid mass which did not invade into the perinephric adipose tissue.
Microscopically, the adrenal mass had predominant diffuse sheets and focal trabecular arrangements. The former pattern was present in about third of tumor. The cells had clear cytoplasm and round to ovoid nuclei with conspicuous nucleoli. Mitotic rate was 9/50 HPF and included atypical forms. Gross necrosis and capsular invasion were documented microscopically. There was no evidence of lymphovascular invasion. Considering the above mentioned features, a Weiss histopathologic score2 of 7/9 was applied.
The differential diagnosis included Renal Cell Carcinoma (RCC) with contralateral adrenal metastasis, Adrenocortical carcinoma (ACC) with contralateral renal metastasis, synchronous RCC and ACC or synchronous RCC and adrenocortical adenoma. A panel of immunohistochemical stains was performed to sort out the diagnosis. Adrenal tumor demonstrated strong Vimentin positivity and is negative for CK7, CK20, E1/AE3, EMA, Synaptophysin and S100.Renal cell carcinoma was positive for CK7, AE1/AE3, EMA (weak) and Vimentin. It was negative for CK20, Synaptophysin and S100. The difference of immunoprofile between the two tumors documented that they originated from two different primaries.
The diagnosis of synchronous RCC and ACC rather than metastasis influences the prognosis.
The longest disease free interval after removal of contralateral adrenal metastasis was 12.1 years8 and the longest crude survival was 14.3 years. In contrast non metastazing RCC has an excellent prognosis if no metastasis developed.